A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- advanced/metastatic solid tumors
- Registration Number
- 2023-504855-28-00
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ended
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Amsterdam UMC
🇳🇱Amsterdam, Netherlands
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
🇳🇱Amsterdam, Netherlands
Amsterdam UMC🇳🇱Amsterdam, NetherlandsMariette LabotsSite contact+31204444875medonc-phase1@amsterdamumc.n